Stelis Biopharma Limited, a biopharma and vaccines company and the biotech arm of Strides Pharma Science has appointed Mark W. Womack as its new chief executive officer (CEO).

Mark W. Womack is also the designated managing director and will be inducted to the board of directors later depending on the required statutory clearances and processes.

As the CEO and MD of Stelis Biopharma, Mark W. Womack will be responsible for driving an aggressive growth and profitability strategy for the company in its business streams, which include global contract development and manufacturing organization (CDMO) services and the development of the biosimilars pipeline and integrated vaccines play.

Mark W. Womack will also take care of the company’s overall strategy and provide leadership to research and development, business development, manufacturing, and commercial operations.

Arun Kumar — Founder of Strides Group said: “We are delighted to onboard Mark as the new CEO of Stelis. Stelis stands on the cusp of a transition to become a globally recognized biopharmaceutical company while targeting significant growth in the coming years.

“Mark’s strong background in commercial leadership, rich management consulting experience, and network within the biotech CDMO space make him exceptionally well suited to drive this transition for Stelis.

“We are confident that together Mark and his leadership team will take Stelis through the next level of growth, profitability and industry-leading reputation.”

  Arun Kumar, India, Mark W. Womack, Stelis Biopharma, Strides Group, Strides Pharma Science